& Option Pit
Good day, 360!
Here are some of our top movers today. And don’t forget to join us in Market Masters – the hottest trading room around 🔥. Be the best prepared trader on the Street!
FOCUS LIST🔎
DEVS – Up over 60% in the pre-market after announcing MoU with Fayafi Investment Holding to explore creation of “Fayafi x DevvStream Green Ventures” to accelerate global sustainability investments
LUCY – Up over 40% in pre after reporting better than expected financial results
SEPN – Up over 60% in pre after announcing $2.2 billion deal with Novo Nordisk a to develop new obesity treatments
*sponsored by The Rundown AI
Learn AI in 5 minutes a day
This is the easiest way for a busy person wanting to learn AI in as little time as possible:
Sign up for The Rundown AI newsletter
They send you 5-minute email updates on the latest AI news and how to use it
You learn how to become 2x more productive by leveraging AI
HOTLIST🔥
DEVS – Up over 60% in the pre-market after announcing MoU with Fayafi Investment Holding to explore creation of “Fayafi x DevvStream Green Ventures” to accelerate global sustainability investments
DevvStream Corp. (DEVS) is a leading carbon management firm that engages in the development, investment, and sale of environmental assets, energy transition, and innovative carbon management solutions in Canada.
In the after-hours yesterday, the company announcedthat it has signed a Memorandum of Understanding (MoU) with Fayafi Investment Holding, one of the UAE’s most forward-thinking and diversified investment platforms.
The agreement outlines the intent to launch Fayafi x DevvStream Green Ventures, a global joint venture designed to accelerate investment in decarbonization and climate infrastructure projects worldwide.
Firm agreements are expected in Q2 2025, with initial project deployments targeted for Q3/Q4 2025. The initial funding commitment is expected to be $100 million, with the potential to scale significantly based on project performance and capital deployment efficiency.
Shares of DEVS traded up over 60% in the pre-market in reaction to the news.
The $0.88 area acted as support in the pre-market and will be an important level to watch.
Above it, targets to the upside are $0.95, $1.02 and then the pre-market high at $1.04. Beyond that, $1.30 and $1.90 come into play.
Below $0.88, targets to the downside are $0.83, $0.80, $0.70, $0.65 and then a gap fill at $0.57.
LUCY – Up over 40% in pre after reporting better than expected financial results
Innovative Eyewear Inc. (LUCY) engages in the development and sale of smart eyeglasses and sunglasses in North America under the Lucyd®, Nautica®, Eddie Bauer® and Reebok® brands.
In the after-hours yesterday, the company announcedits Q1 2025 Unaudited financial results.
Highlights include:
Net revenue for the quarter ended March 31, 2025 was $454,501 an increase of 19% from revenue of $383,471 in the quarter ended March 31, 2024.
Gross profit margin for Q1 2025 was 49%, compared with 2% for Q1 2024, driven by lower cost of frames and lower prescription lens fulfilment cost.
The Company had a net loss in Q1 2025 of $1,778,703, or $(0.72) per share, compared with a net loss of $1,971,311, or $(2.59) per share, in Q1 2024.
Shares of LUCY traded up over 40% in the pre-market in reaction to the positive financial results.
The $2.75 area acted as support in the pre-market and will be an important level to watch.
Above it, targets to the upside are $3, $3.20, $3.40 and then the pre-market high at $3.97. Beyond that, $4.80 and $5.56 come into play.
Below $2.75, targets to the downside are $2.44 and then a gap fill at $1.98.
*together with Option Pit
New Announcement From Olivia Voz:
Make Your FIRST GAME PLAN TRADE Class Starts Monday!
Only Available To 100 50 New Members.
Dial 888-872-3301 With ANY Questions.
SEPN – Up over 60% in pre after announcing $2.2 billion deal with Novo Nordisk a to develop new obesity treatments
Septerna Inc. (SEPN) is a clinical-stage biotechnology company that discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases.
In the pre-market this morning, it was reported that Novo Nordisk (NVO) had signed a licensing deal with Septerna to develop oral small molecule medicines for obesity, type 2 diabetes and other cardio-metabolic diseases that could be worth up to $2.2 billion.
Novo, is the producer of the successful Wegovy weight-loss drug and had a market cap of over $220 billion based on yesterday’s close according to Finviz.
Shares of SEPN traded up over 60% in the pre-market in reaction to the news.
The $10.60 area acted as support in the pre-market and will be an important level to watch.
Above it, targets to the upside are $11.15 and then the pre-market high at $12.28. Beyond that, $13.19 and $14 come into play.
Below $10.60, targets to the downside are $10, $9, $8 and then a gap fill at $6.73.
MARKET NEWS 📰
Don’t miss out on our MOBILE ALERTS! Some of these alerts have rocketed 🚀past the MOON 🌝. Text “RAGE” to 1-(888) 487-1534📲.
*Disclosure: By texting “RAGE” to 1-(888) 487-1534, you agree to receive promotional messages sent via an autodialer. You also agree to the terms of service and privacy policy. This agreement isn’t a condition of any purchase. Message frequency varies. Message and data rates may apply. Reply STOP to opt out; HELP for more information.
DISCLAIMER: To more fully understand any Ragingbull.com, LLC (“RagingBull”) subscription, website, application or other service (“Services”), please review our full disclaimer located at https://ragingbull.com/disclaimer
FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Any RagingBull Service offered is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. RagingBull strongly recommends you consult a licensed or registered professional before making any investment decision.
RESULTS PRESENTED NOT TYPICAL OR VERIFIED. RagingBull Services may contain information regarding the historical trading performance of RagingBull owners or employees, and/or testimonials of non-employees depicting profitability that are believed to be true based on the representations of the persons voluntarily providing the testimonial. However, subscribers’ trading results have NOT been tracked or verified and past performance is not necessarily indicative of future results, and the results presented in this communication are NOT TYPICAL. Actual results will vary widely given a variety of factors such as experience, skill, risk mitigation practices, market dynamics and the amount of capital deployed. Investing in securities is speculative and carries a high degree of risk; you may lose some, all, or possibly more than your original investment.
RAGINGBULL IS NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Neither RagingBull nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. Employees, owners, and other service providers of https:// ragingbull. com or RagingBull.com LLC are paid in whole or in part by commission based on their sales of Services to subscribers.
RagingBull.com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements. In the event that any suit or action is instituted as a result of doing business with RagingBull. com, LLC and/or its affiliates or if any suit or action is necessary to enforce or interpret these Terms of Service, RagingBull. com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements in addition to any other relief to which it may be entitled.
*Sponsored Content:If you purchase anything through a link in this email other than RagingBull (RB) services, you should assume that we have an affiliate relationship with the company providing the product that you purchase, and that we will be paid in some way. RB is not responsible for any content hosted on affiliate’s sites and it is the affiliate’s responsibility to ensure compliance with applicable laws. We recommend that you do your own independent research before purchasing anything. While we believe in the companies we form affiliate relationships with, please don’t spend any money on these products unless you believe they will help you achieve your goals.
WE MAY HOLD SECURITIES DISCUSSED. RagingBull has not been paid directly or indirectly by the issuer of any security mentioned in the Services except possibly by advertisers in this email. However, Ragingbull.com, LLC, its owners, and its employees may purchase, sell, or hold long or short positions in securities of the companies mentioned in this communication.
